Advanced Glycation End Products

    Last Updated: October 13, 2024

    Advanced glycation end products (AGEs) are highly reactive compounds that result from chemical reactions in the body. While their formation is a byproduct of normal metabolism, a growing body of evidence suggest they may be linked with many chronic diseases.

    Summary

    Advanced glycation end products (AGEs) are highly reactive compounds that result from a chemical reaction between reducing sugars and amino acids (also known as a Maillard reaction) and from the oxidation of sugars, lipids, and amino acids. Although the formation of AGEs within the body is a part of normal metabolism, a growing body of evidence[1][2][3] suggests that excessive AGE levels promote oxidative stress and inflammation and may therefore increase the risk of developing type 2 diabetes, cardiovascular disease, fatty liver, cancer, Alzheimer’s disease, and infertility.

    AGEs were first recognized as being produced within the body under conditions of increased oxidative stress. However, it is now known that dietary AGEs are important contributors[4] to the body’s total AGE concentration, where they become indistinguishable[5] from those AGEs produced within the body itself. The most widely studied AGE is carboxymethyllysine (CML), while another common marker of AGE formation is methyl-glyoxal (MG).

    Examine Database: Advanced Glycation End Products

    Research FeedRead all studies

    Examine Database References

    1. Benfotiamine - Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, Scheijen JL, Schalkwijk CG, Navis GJ, Bakker SJEffect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathyPLoS One.(2012)
    2. Coenzyme Q10 - Mirhashemi SM, Najafi V, Raygan F, Asemi ZThe effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trialARYA Atheroscler.(2016 Jul)
    3. Nicotinamide Mononucleotide - Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, Tsuji-Naito KNicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial.Sci Rep.(2023-Feb-16)